Market revenue in 2023 | USD 42,776.6 million |
Market revenue in 2030 | USD 108,807.2 million |
Growth rate | 14.3% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 85.69% in 2023. Horizon Databook has segmented the U.S. precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
PM has gained significant attention in the U.S., especially following the launch of the nationwide Precision Medicine Initiative (PMI), All of Us, in 2015. PM combines genomic and molecular analyses with established clinical indices to achieve more precise disease classification and potentially more effective prevention & treatment across diverse population groups.
This emerging healthcare approach, embraced by U.S. scientists and policymakers, focuses on disease taxonomy without necessarily implying personalized treatment. According to the Personalized Medicine Coalition (PMC), personalized medicines accounted for over one-third of new U.S. FDA drug approvals for the fourth consecutive year in 2023.
This trend toward personalized treatment approvals is especially notable in the area of rare diseases, where the number of new treatment approvals more than doubled last year. In 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Moreover, the newly approved personalized treatments for 2023 include seven cancer drugs and three for other diseases & conditions.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into U.S. precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account